Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

Delayed Quote. Delayed  - 10/21 10:00:00 pm
50.83 USD   -1.49%
10/20 SEATTLE GENETIC : Demonstrates Commitment to Improve Hodgkin Lymphom..
10/19 TAKEDA PHARMACE : Showcases Continued Commitment in Hodgkin Lymphoma..
10/12 SEATTLE GENETIC : and Agensys, an Affiliate of Astellas, Highlight E..
News SummaryMost relevantAll newsSector news 

Seattle Genetics, Inc. : Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 12:10am CEST

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the company's poster presentations is below and full abstracts can be accessed on the ASCO website at www.abstract.asco.org.


Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study

  • Saturday, June 2; 8:00 a.m. - 1:00 p.m. Central Time (CT), with discussion from 12:00 p.m. - 1:00 p.m. CT
  • Abstract # 8027
  • Poster display in room E450b and discussion in room E354a
  • First author: Dr. Nancy L. Bartlett, Washington University, Siteman Cancer Center, St. Louis, MO

CD30 expression in non-lymphomatous malignancies

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT
  • Abstract #3069
  • Poster presentation in S Hall A2; poster board #16C
  • First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute and Research Center, Eugene, OR

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

  • Monday, June 4; 1:15 p.m. - 5:15 p.m. CT
  • Abstract #8070
  • Poster presentation in S Hall A2; poster board #35C
  • First author: Dr. Ranjana Advani, Stanford University Medical Center, Stanford, CA


Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC)

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT, with discussion from 11:30 a.m. - 12:30 p.m. CT
  • Abstract #4568
  • Poster display in room E450a and discussion in room E Arie Crown Theater
  • First author: Dr. Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY


ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Seattle Genetics and Millennium: The Takeda Oncology Company are jointly developing ADCETRIS.

Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group is solely responsible for development costs.

About ASG-5ME

ASG-5ME is an ADC targeting the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors. ASG-5ME is an ADC composed of a fully human antibody directed to SLC44A4, a solute carrier antigen family member identified by Agensys to be overexpressed in epithelial cancers, including more than 80 percent of samples derived from patients with prostate, pancreatic and gastric cancers. The antibody is attached to MMAE via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
10/20 SEATTLE GENETICS : Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment..
10/19 TAKEDA PHARMACEUTICAL : Showcases Continued Commitment in Hodgkin Lymphoma Durin..
10/14 SEATTLE GENETICS : Assigned Patent
10/12 SEATTLE GENETICS INC /WA : Other Events, Financial Statements and Exhibits (form..
10/12 SEATTLE GENETICS : and Agensys, an Affiliate of Astellas, Highlight Enfortumab V..
10/07 SEATTLE GENETICS : and Agensys, an Affiliate of Astellas, Highlight Promising En..
10/06 SEATTLE GENETICS : Patent Issued for Activated Carbon Filtration for Purificatio..
10/06 SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of Third Quart..
10/04 SEATTLE GENETICS : Announces Executive Promotions and Leadership Appointment
09/30 SEATTLE GENETICS : Assigned Patent
More news
Sector news : Biotechnology & Medical Research - NEC
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
10/17 Biotechs Fearing An Election Sweep, Erroneously Turn Tail
10/14 European Ad Comm backs Bristol-Myers' Opdivo for specific use in Hodgkin lymp..
10/10 Lively M&A Scene Keeps Biotech Shares Buoyant In Q3
09/29 AML THERAPIES PART 2 : Agios And ImmunoGen
09/29 Yellen And Clinton Combo To Take Market Higher
Financials ($)
Sales 2016 417 M
EBIT 2016 -143 M
Net income 2016 -146 M
Finance 2016 430 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 16,2x
EV / Sales 2017 13,7x
Capitalization 7 193 M
More Financials
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Full-screen chart
Technical analysis trends SEATTLE GENETICS,...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 51,7 $
Spread / Average Target 1,7%
Consensus details
EPS Revisions
More Estimates Revisions
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 863
LONZA GROUP AG13.92%9 846
ALKERMES PLC-29.93%8 430
More Results